Interventions are needed that stress the limitations of current antiretroviral medications. These medications do not work for everyone, and even when they do work, they can cause deleterious side effects (e.g., body dysmorphic disorders related to HAART, i.e., lipodystrophy) and can be difficult to tolerate (Rabkin and Chesney, 1999). Interventions must also drive home the fact that almost 25% of newly infected persons are resistant to all three current classes of medications, and nearly 80% display resistance to at least one class of antiretrovirals (Voelker, 2000). This severely limits current and possibly future treatment options (Hecht et al., 1998; Wainberg and Friedland, 1998).